HDAC9 and neoplasm: Indeed, mocetinostat elicited a similar effect on adoptively transferred CTLs, but not to the same extent as butyrate and pentanoate, while the class II HDAC inhibitor TMP-195 did not enhance CTL-mediated anti-tumor immune responses (Fig. 3b–g).